Search results for "c-MET"

showing 10 items of 47 documents

The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis

2012

Lethal giant larvae proteins have key roles in regulating polarity in a variety of cell types and function as tumour suppressors. A transcriptional programme initiated by aberrant Snail expression transforms epithelial cells to potentially aggressive cancer cells. Although progress in defining the molecular determinants of this programme has been made, we have little knowledge as to how the Snail-induced phenotype can be suppressed. In our studies we identified the human lethal giant larvae homologue 2, Hugl-2, (Llgl2/Lgl2) polarity gene as downregulated by Snail. Snail binds E-boxes in the Hugl-2 promoter and represses Hugl-2 expression, whereas removal of the E-boxes releases Hugl-2 from …

Cancer ResearchCell typeMice SCIDSnailmedicine.disease_causeMiceMice Inbred NODbiology.animalChlorocebus aethiopsparasitic diseasesCell polarityGeneticsmedicineAnimalsHumansGenes Tumor SuppressorNeoplasm MetastasisMolecular BiologyTranscription factorCells CulturedRegulation of gene expressionbiologyfungiHEK 293 cellsCell PolarityHep G2 CellsAnatomyProto-Oncogene Proteins c-metXenograft Model Antitumor AssaysPhenotypeUp-RegulationCell biologyGene Expression Regulation NeoplasticCytoskeletal ProteinsCell Transformation NeoplasticHEK293 CellsCOS CellsSnail Family Transcription FactorsCarcinogenesisProtein BindingTranscription FactorsOncogene
researchProduct

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers

2022

Abstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted cancers), an efficient block of its oncogenic activation results in potent tumor growth inhibition. Methods Here we describe a molecular engineered MET antibody (hOA-DN30) and validate its pharmacological activity in MET-addicted cancer models in vitro and in vivo. Pharmacokinetics and safety profile in non-human primates have also been assessed. Results hOA-DN30 efficiently impaired MET activation and the intracellular signalling cascade by dose and time dependent removal of the receptor fr…

Cancer ResearchTumorCorrectionProto-Oncogene Proteins c-metCell LineTargeted therapyMiceAntibody; Gastric cancer; MET oncogene; Targeted therapy; Animals; Cell Line Tumor; Cell Proliferation; Humans; Mice; Signal Transduction; Proto-Oncogene Proteins c-met; Stomach NeoplasmsOncologyStomach NeoplasmsCell Line TumorMET oncogeneAnimalsHumansGastric cancerAntibodyCell ProliferationSignal TransductionJournal of Experimental & Clinical Cancer Research
researchProduct

Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways

2020

The quinoline ring system has long been known as a versatile nucleus in the design and synthesis of biologically active compounds. Currently, more than one hundred quinoline compounds have been approved in therapy as antimicrobial, local anaesthetic, antipsychotic, and anticancer drugs. In drug discovery, indeed, over the last few years, an increase in the publication of papers and patents about quinoline derivatives possessing antiproliferative properties has been observed. This trend can be justified by the versatility and accessibility of the quinoline scaffold, from which new derivatives can be easily designed and synthesized. Within the numerous quinoline small molecules developed as a…

Cell SurvivalAngiogenesisPharmaceutical ScienceAntineoplastic AgentsReviewMolecular Dynamics SimulationAnalytical Chemistrylcsh:QD241-441Structure-Activity Relationship03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:Organic chemistryEpidermal growth factorquinolineDrug DiscoverySAR studieHumansPhysical and Theoretical Chemistrycarcinogenic pathwaysProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesantiproliferative compoundChemistryDrug discoveryOrganic ChemistryQuinolineBiological activityProto-Oncogene Proteins c-metantiproliferative compoundstargeted therapySettore CHIM/08 - Chimica FarmaceuticaSmall moleculeErbB Receptorscarcinogenic pathwayReceptors Vascular Endothelial Growth FactorSAR studiesChemistry (miscellaneous)030220 oncology & carcinogenesisQuinolinesCancer researchMolecular Medicinekinases modulatorkinases modulatorsbiological dataSignal TransductionMolecules
researchProduct

Thiocarbamate-Linked Polysulfonate–Peptide Conjugates As Selective Hepatocyte Growth Factor Receptor Binders

2014

The capacity of many proteins to interact with natural or synthetic polyanions has been exploited for modulating their biological action. However, the polydispersity of these macromolecular polyanions as well as their poor specificity is a severe limitation to their use as drugs. An emerging trend in this field is the synthesis of homogeneous and well-defined polyanion–peptide conjugates, which act as bivalent ligands, with the peptide part bringing the selectivity of the scaffold. Alternately, this strategy can be used for improving the binding of short peptides to polyanion-binding protein targets. This work describes the design and first synthesis of homogeneous polysulfonate–peptide con…

DendrimersBiomedical EngineeringPharmaceutical ScienceBioengineeringPeptidemacromolecular substancesPlasma protein bindingArticleReceptor tyrosine kinaseSubstrate SpecificityStructure-Activity RelationshipThiocarbamatesmedicineHumansStructure–activity relationshipPharmacologychemistry.chemical_classificationDose-Response Relationship DrugMolecular StructurebiologyHepatocyte Growth FactorChemistryOrganic Chemistrytechnology industry and agricultureProto-Oncogene Proteins c-metProtein Structure TertiaryThiocarbamateBiochemistryHepatocyte Growth Factor ReceptorProto-Oncogene Proteins c-metbiology.proteinHepatocyte growth factorSulfonic AcidsPeptidesProtein BindingBiotechnologymedicine.drugBioconjugate Chemistry
researchProduct

From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-me…

2014

We synthesized a series of serum-stable covalently linked drugs derived from 3'-C-methyladenosine (3'-Me-Ado) and valproic acid (VPA), which are ribonucleotide reductase (RR) and histone deacetylase (HDAC) inhibitors, respectively. While the combination of free VPA and 3'-Me-Ado resulted in a clear synergistic apoptotic effect, the conjugates had lost their HDAC inhibitory effect as well as the corresponding apoptotic activity. Two of the analogs, 2',5'-bis-O-valproyl-3'-C-methyladenosine (A160) and 5'-O-valproyl-3'-C-methyladenosine (A167), showed promising cytotoxic activities against human hematological and solid cancer cell lines. A167 was less potent than A160 but had interesting featu…

Deoxyribonucleoside triphosphateAdenosineCell SurvivalClinical BiochemistryAllosteric regulationPharmaceutical ScienceAntineoplastic AgentsPharmacologyBiochemistryHistone deacetylase (HDAC) inhibitorHistone DeacetylasesAdenosine TriphosphateAllosteric RegulationCell Line TumorDrug DiscoveryRibonucleotide ReductasesmedicineValproic acidHumansRibonucleotide reductase (RR) inhibitorEnzyme InhibitorsMolecular Biology3′-C-methyladenosineNucleoside analogueKinaseChemistryOrganic ChemistryApoptosiEstersSettore CHIM/08 - Chimica FarmaceuticaHematological and solid tumorHistone Deacetylase InhibitorsKineticsRibonucleotide reductaseBiochemistrySettore BIO/14 - FarmacologiaMolecular MedicineHistone deacetylaseNucleosideIntracellularmedicine.drug
researchProduct

The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

2014

Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal-epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpr…

Lung NeoplasmscMETcMET; cMET-Inhibitors; EGFR-TKIs resistance; HGF; NSCLC; Targeted therapies; Molecular Medicine; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAntineoplastic AgentsBiologyPharmacologyNSCLCReceptor tyrosine kinaseTargeted therapiesCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansEpidermal growth factor receptorHGFLung cancerProtein Kinase InhibitorsEGFR inhibitorsEGFR-TKIs resistancePharmacologyClinical Trials as TopicPharmacology. TherapyDrug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalProto-Oncogene Proteins c-metmedicine.diseaseMolecular medicinerespiratory tract diseasesErbB ReceptorsDrug Resistance NeoplasmProto-Oncogene Proteins c-metbiology.proteinCancer researchMolecular MedicineDrug Therapy CombinationHepatocyte growth factorcMET-InhibitorTargeted therapiecMET-InhibitorsTyrosine kinasemedicine.drug
researchProduct

Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype

2019

Abstract Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-KitW-sh/W-sh (Wsh) mice, showed that MCs promote tumor growth and prevent the development of basal CK5-positive areas in favor of a luminal gene program. When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET, a master regulator of the basal pr…

Male0301 basic medicineCancer ResearchReceptor ErbB-2Estrogen receptorBreast NeoplasmsMice TransgenicCell CommunicationCell Growth ProcessesMice03 medical and health sciences0302 clinical medicineBreast cancerImmune systemCell Line TumormedicineAnimalsHumansMast CellsNeoplasm Metastasisskin and connective tissue diseasesEstrogen receptor activityMice Inbred BALB Cbusiness.industryMammary Neoplasms ExperimentalCancerProto-Oncogene Proteins c-metmedicine.diseaseMast cellPhenotypeErbB ReceptorsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureReceptors EstrogenOncology030220 oncology & carcinogenesisCancer researchFemalebusinessmast cell estrogen receptor breast cancer luminal phenotypeEstrogen receptor alpha
researchProduct

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.

2015

Genetic and epigenetic alterations play an important role in gastric cancer (GC) pathogenesis. Aberrations of the phosphatidylinositol-3-kinase signaling pathway are well described. However, emerging genes have been described such as, the chromatin remodeling gene ARID1A. Our aim was to determine the expression levels of four GC-related genes, ARID1A, CDH1, cMET and PIK3CA, and 14 target-related microRNAs (miRNAs). We compared mRNA and miRNA expression levels among 66 gastric tumor and normal adjacent mucosa samples using quantitative real-time reverse transcription PCR. Moreover, ARID1A, cMET and PIK3CA protein levels were assessed by immunohistochemistry (IHC). Finally, gene and miRNAs as…

MaleARID1AClass I Phosphatidylinositol 3-KinasesReal-Time Polymerase Chain ReactionCDH1Epigenesis GeneticPhosphatidylinositol 3-KinasesAntigens CDStomach NeoplasmsGene expressionmicroRNAmedicineBiomarkers TumorHumansRNA MessengerAgedbiologyReverse Transcriptase Polymerase Chain ReactionGene Expression Profilinggastric cancerCancerNuclear ProteinsbiomarkersMiddle AgedProto-Oncogene Proteins c-metmedicine.diseaseCadherinsMolecular biologyImmunohistochemistryChromatinGene expression profilingReverse transcription polymerase chain reactionDNA-Binding ProteinsGene Expression Regulation NeoplasticMicroRNAsReal-time polymerase chain reactionmicrorna expressionOncologyGastric Mucosabiology.proteingene expressionFemaleTranscription FactorsResearch PaperOncotarget
researchProduct

CHARACTERIZATION OF A NEW RAT CELL LINE ESTABLISHED FROM 2′AAF-INDUCED COMBINED HEPATOCELLULAR CHOLANGIOCELLULAR CARCINOMA

2001

A rat cell line-nominated CC-62 derived from a combined hepatocellular and cholangiocellular carcinoma obtained by administration of 2-acetylaminofluorene to male Wistar rats, has been established. Using light and electron microscopy it was determined that morphologically the tumor consisted of a mixed population of hepatocytes and cholangiolar neoplastic cells, intermingled with small, undifferentiated oval-like cells. The CC-62 line has been maintained through 90 passages in culture adopting a paving stone arrangement. Doubling time at the 12th passage was 23 h. Immunostaining with a panel of antisera was performed to identify the cytological profiles of the cell line. There was no k-ras …

MaleCarcinoma HepatocellularC-MetTransplantation HeterologousPopulationCellMice NudeHistogenesisBiologyCholangiocarcinomaMicechemistry.chemical_compoundTumor Cells CulturedCarcinomamedicineAnimalsRats Wistareducationeducation.field_of_studyHepatocyte Growth FactorReverse Transcriptase Polymerase Chain ReactionLiver NeoplasmsDNA NeoplasmCell BiologyGeneral Medicine2-AcetylaminofluoreneProto-Oncogene Proteins c-metAneuploidymedicine.diseaseImmunohistochemistryMolecular biologyRatsTransplantationMicroscopy ElectronBile Ducts IntrahepaticGenes rasmedicine.anatomical_structureBile Duct NeoplasmschemistryCell cultureKaryotypingTumor Suppressor Protein p53ImmunostainingDevelopmental BiologyIn Vitro Cellular & Developmental Biology - Animal
researchProduct

Effect of c-Met expression on survival in head and neck squamous cell carcinoma

2005

The proto-oncogene c-Met has been suggested to be associated with progression of squamous cell carcinoma of the head and neck. The aims of the present study were to assess the prevalence of c-Met expression in oral squamous cell carcinoma (OSCC) and to verify whether c-Met can be considered a marker of prognosis in these patients. In a retrospective study, a cohort of 84 OSCC patients was investigated for c-Met expression and its cellular localization by immunohistochemistry. After grouping for c-Met expression, OSCC patients were statistically analyzed for the variables age, gender, histological grading, tumor node metastasis, staging and overall survival rate. Univariate and multivariate …

OncologyAdultMalemedicine.medical_specialtyc-Met; Cox regression analysis; Oral squamous cell carcinoma;C-MetAdolescentcox regression analysisProto-Oncogene Maschemistry.chemical_compoundInternal medicinemedicineBiomarkers TumorHumansBasal cellHead and neckc-MetNeoplasm Stagingbusiness.industryMouth MucosaGeneral MedicineMiddle AgedProto-Oncogene Proteins c-metmedicine.diseasePrognosisHead and neck squamous-cell carcinomaImmunohistochemistryUp-Regulationoral squamous cell carcinomastomatognathic diseaseschemistryCarcinoma Squamous CellFemaleMouth Neoplasmsbusiness
researchProduct